Might be AEK, I make no reps on him being involved with characterizing DCVax’ success and that’s basically what I said, it would be a conflict to work for both, so he has a better offer at this time with DCVax/NWBO. However, characterizing the placebo, the standard of care, is his expertise, and part of doing that for the trial means doing it while the data was still blind. He is also an unbiased source because he created the standard of care in actuality, so there is likely no better source for that data, which given the later switch to historical controls, it is compelling. It’s about as compelling as one can get.
So my guess is, that is WHY he is consulting. He’s the top expert at characterizing the Standard of Care or What will be the placebo arm. It is difficult for anyone therefore to question the verify of a synthetic placebo arm he might create as “biased” in any ways. That’s my opinion. Having been a skeptic, that is an even better verification. And in that context, whether he ultimately later saw unblinded data or not, the key would be his expertise at the SOC side of the trial.
Market Data 
Markets 
AI
